Literature DB >> 26561040

Emerging innovations in clinical trial design.

D A Berry1.   

Abstract

Designs of clinical trials have changed little since the advent of randomization in the 1940s. Modern innovations in designs are being driven by the increasing recognition in clinical research that diseases are heterogeneous and patients who apparently have the same disease require different therapies. This article describes some innovations in clinical trial design across therapeutic areas but with a focus on oncology. No one knows what the future holds for clinical trial design but the status quo of large trials that pretend the patient population is homogeneous is not sustainable, either economically or scientifically/medically. No one knows what the eventual business model and regulatory model will be, but they will be very different from today's.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2015        PMID: 26561040     DOI: 10.1002/cpt.285

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  EFFICACY-TO-EFFECTIVENESS CLINICAL TRIALS.

Authors:  Harry P Selker; Sheeona Gorman; Kenneth I Kaitin
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

2.  Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Authors:  Roland B Walter; Laura C Michaelis; Megan Othus; Geoffrey L Uy; Jerald P Radich; Richard F Little; Sandi Hita; Lalit Saini; James M Foran; Aaron T Gerds; Heidi D Klepin; Annette E Hay; Sarit Assouline; Jeffrey E Lancet; Stephen Couban; Mark R Litzow; Richard M Stone; Harry P Erba
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

3.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

4.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10

5.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Authors:  Donald A Berry; Shouhao Zhou; Howard Higley; Lata Mukundan; Shuangshuang Fu; Gregory H Reaman; Brent L Wood; Gary J Kelloff; J Milburn Jessup; Jerald P Radich
Journal:  JAMA Oncol       Date:  2017-07-13       Impact factor: 31.777

6.  PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Authors:  M R Trusheim; A A Shrier; Z Antonijevic; R A Beckman; R K Campbell; C Chen; K T Flaherty; J Loewy; D Lacombe; S Madhavan; H P Selker; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

Review 7.  A reintroduction of environmental mite allergen control strategies for asthma treatment and the debate on their effectiveness.

Authors:  Frank E van Boven; Lidia R Arends; Gert-Jan Braunstahl; Roy Gerth van Wijk
Journal:  Clin Exp Allergy       Date:  2019-02-11       Impact factor: 5.018

8.  First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug.

Authors:  Vincenzo Teneggi; Veronica Novotny-Diermayr; Lay Hoon Lee; Maryam Yasin; Pauline Yeo; Kantharaj Ethirajulu; Sylvia Bong Hwa Gan; Stephanie E Blanchard; Ranjani Nellore; Dhananjay N Umrani; Roberto Gomeni; Darren Lim Wan Teck; Greg Li; Qing Shu Lu; Yang Cao; Alex Matter
Journal:  Clin Transl Sci       Date:  2019-09-09       Impact factor: 4.689

Review 9.  Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children.

Authors:  Stephen J Balevic; Michael Cohen-Wolkowiez
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 2.860

10.  Signature program: a platform of basket trials.

Authors:  Eric D Slosberg; Barinder P Kang; Julio Peguero; Matthew Taylor; Todd M Bauer; Donald A Berry; Fadi Braiteh; Alexander Spira; Funda Meric-Bernstam; Steven Stein; Sarina A Piha-Paul; August Salvado
Journal:  Oncotarget       Date:  2018-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.